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To explore the possibility of conferring a long-term resistance against human immunodeficiency virus (HIV) by a low
continuous production of interferon-b (IFN-b) in hematopoietic progenitor cells, we transduced the human CD341 TF-1 cells
with a retroviral vector ensuring IFN-b production. The IFN-b-transduction of TF-1 cells resulted in resistance to infection
with HIV-LAI, as shown by the selective survival of IFN-b-transduced CD41 cells and the protection against HIV-induced
apoptosis. A similar response against HIV-LAI infection was obtained after pretreatment with 100 U/ml of recombinant
IFN-a2b or IFN-b. In contrast, after the addition of macrophage cell tropic (M cell-tropic) HIV strain, a treatment with
exogenous IFN-a2b resulted in a ^10-fold lower protection compared with exogenous IFN-b or IFN-b transduction. This
specific effect of IFN-b on M cell-tropic HIV strains was correlated with a down-regulation of the CCR-5 chemokine receptor
expression, corresponding to a novel antiviral effect of IFN-b. © 1999 Academic Press
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Several defects in hematopoiesis have been reported
n human immunodeficiency virus (HIV)-infected individ-
als, leading to hematological disorders, including ane-
ia, granulocytopenia, thrombocytopenia, and myelo-
ysplastic/hyperplastic alterations of the bone marrow
Scaden et al., 1989). Both direct killing and indirect
poptotic effects on CD341 hematopoietic progenitor
ells have been observed in the presence of HIV. These
ematopoietic progenitor cells are potential target cells
or HIV-1 because 25–50% of CD341 cells express the
D4 cell surface marker, which serves as high-affinity
eceptor for HIV-1 (Louache et al., 1994), and in vitro, the
resence of HIV proviral sequences has been detected
n the ensuing colonies of erythroid and myeloid lin-
ages generated from HIV-infected CD341 cells (Che-
ucci et al., 1995).
To establish an HIV resistance in CD341 progenitor
ells, we investigated a somatic cell gene therapy based
n the multiple antiretroviral activities of interferon
IFN)-b, which affects multiple stages of the HIV life
ycle, including penetration, transcription, virion assem-
ly, and budding (De Maeyer and De Maeyer-Guignard,
998; Francis et al., 1992; Michaelis et al., 1989). Clinical
rials with high concentrations of IFN-a have been con-
ucted on patients with acquired immune deficiency
yndrome, but only transient effects on the disease have
1 To whom reprint requests should be addressed at Batiment 110.
nax: 011-33-1-69-07-83-21.
241een obtained (Lane et al., 1990). Moreover, type I IFNs
ave induced frequent side effects in individuals, includ-
ng fever, malaise, rashes, and headache, that some-
imes result in interruption of the treatment. IFN-b has
een described to be less toxic than IFN-a on hemato-
oietic progenitor cells (Broxmeyer et al., 1983). Our
pproach consists of establishing an anti-HIV state in
ells through the low continuous synthesis of IFN-b
Mace´ et al., 1991). For this purpose, we constructed the
MB-KbHuIFNb retroviral vector carrying the human
FN-b coding sequence under the constitutive expres-
ion control of a murine H-2Kb gene promoter fragment
Vieillard et al., 1997). We have previously shown that the
FN-b transduction of peripheral blood lymphocytes
PBLs) from uninfected or from HIV-infected donors in-
ibited virus replication, favored survival of CD41 T cells,
nhanced Th-1-like cytokine production, and improved
he proliferative response of CD41 T cells to recall anti-
ens (Vieillard et al., 1997). These observations
rompted us to investigate the possibility of obtaining a
ong-term antiviral state in all possible target cells of HIV,
ncluding T cells, monocytes/macrophages, and den-
ritic cells, by transduction of CD341 hematopoietic pro-
enitor cells with the HMB-KbHuIFNb retroviral vector.
To investigate the effects of a low constitutive expres-
ion of IFN-b on the HIV resistance of human CD341
ells, we used the CD341 TF-1 cell line as a model of
ematopoietic progenitor cells (Kitamura et al., 1989). We
nalyzed the HIV-1 resistance of IFN-b-transduced TF-1
ells and compared the effect of the addition of exoge-
ous IFN-a2b or IFN-b on TF-1 cells, challenged with
0042-6822/99 $30.00
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242 CREMER, VIEILLARD, AND DE MAEYERither T cell-tropic or M cell-tropic HIV strains. We report
protective effect of IFN-b transduction against HIV-LAI
nfection, accompanied by a survival advantage of IFN-
-transduced TF-1 cells, resulting from a resistance to
he apoptosis induced by HIV. In addition, our results
emonstrate that IFN-b treatment blocked the infection
f TF-1 cells by M cell-tropic HIV strains specifically and
ore efficiently than IFN-a2b; this was correlated with an
nhibition of the CCR-5 chemokine receptor expression.
RESULTS
Enhancement of HIV-LAI resistance in IFN-b-trans-
uced TF-1 cells. The effect of a low, constitutive expres-
ion of IFN-b on HIV-1 resistance in CD341 hematopoi-
tic cells was examined using the CD341 TF-1 cell line
ransduced by the HMB-KbHuIFNb retroviral vector. As
hown in Table 1, in two experiments, the cells were
ransduced with the IFN-b transgene with an efficacy of
35% and produced a low level of IFN corresponding to
28 U/105 cells/48 h, measured 4 days after the IFN-b
ransduction (Table 1). The analysis of cell surface mark-
rs revealed that 100% of untransduced, neo-trans-
uced-, and IFN-b-transduced cells were strongly posi-
ive for the CD34 marker (data not shown), and ;50%
f TF-1 cells expressed low levels of the CD4 marker
Table 1).
One day after IFN-b transduction, the cells were chal-
enged with the T cell-tropic HIV-LAI strain at a m.o.i.
lose to 0.01. In untransduced control cells, the cell
iability steadily decreased until day 4 and then in-
reased at the same level as that for uninfected cells
Fig. 1A). This slight decrease in cell viability was corre-
ated with an increase of HIV DNA copy number per cell,
hich steadily increased to reach an average copy num-
er of 0.3 on day 4 and then declined progressively to
TABLE 1
Characteristics of Untransduced, Neo-transduced-, and IFN-b-
transduced TF-1 Cells 4 Days after Onset of HIV-LAI Infection
Percent
transduction
IFN production
(U/105 cells/48 h)
Percent of CD41-
expressing cells
xperiment 1
UT/UI ,3 44
UT/HIV ,3 18
IF-T/UI 34 25 45
IF-T/HIV 64 44 41
xperiment 2
Neo-T/UI 42 ,3 56
Neo-T/HIV 51 ,3 18
IF-T/UI 39 32 45
IF-T/HIV 63 66 38
Note. UT, untransduced cells; IF-T, IFN-b-transduced cells; Neo-T,
eo-transduced cells; UI, uninfected cells; HIV, HIV-LAI-infected cells.isappear completely within 12 days (Fig. 1B). At this time, there was a ;2-fold decrease in the percentage of
D41-expressing cells (Table 1). The p24 production in
hese control cells remained close to background level
data not shown) (i.e., inferior to 30 pg/ml), indicating that
IV-LAI infection of TF-1 cells is not productive. As
hown in Fig. 2, similar results were obtained with neo-
FIG. 1. Kinetics of the HIV resistance of IFN-b-transduced TF-1 cells.
A) Cell viability of untransduced and IFN-b-transduced cells. The
ercentage of cell viability was calculated every 2 days by dividing the
otal number of cells in the population infected by HIV-LAI () by the
umber of cells present in uninfected cultures (n), taken to be 100%. (B)
volution of HIV DNA copies (HIV) and HMB-KbHuIFNb integrations
IF-T) in untransduced (UT) and IFN-b-transduced cell populations,
easured at days (D) 0, 2, 4, 6, and 12 after HIV-LAI infection.
FIG. 2. Analysis of resistance against T cell-tropic (BRU) and M
ell-tropic (BAL, YU-2) HIV strains of neo-transduced (neo-T) and IFN-
-transduced (IFN-T) TF-1 cells at days 2 and 12 after onset of HIV
nfection. UI indicates uninfected cells; HIV, HIV-infected cells; UT,
ntransduced cells; UT 1 1 copy, one copy of neo transgene, IFN-bransgene, and HIV DNA.
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243IFN-b-MEDIATED HIV RESISTANCE IN CD341 CELLSransduced TF-1 cells after the addition of the HIV-LAI
nfectious particles. We observed a temporary increase
f the HIV DNA copy number per cell, to reach an
verage of 0.6 on day 2 and then to disappear at day 12.
In the IFN-b-transduced cells exposed to HIV-LAI, the
ell viability was not altered (Fig. 1A), the number of HIV
NA copies per cell remained inferior to 0.01 (Figs. 1B
nd 2), and the percentage of CD41 cells remained at the
evel of ;55% observed in the uninfected cells (Table 1).
reatment with IFN-a2b or with IFN-b induced in TF-1
ells a similar resistance against the T cell-tropic HIV-
FIG. 3. Kinetics of resistance against T cell-tropic (BRU) and M
ell-tropic (BAL, YU-2) HIV strains of untreated, IFN-a-treated, or IFN-
-treated TF-1 cells. (A) Cell viability of untreated, IFN-a2b-treated, and
FN-b-treated cells. The percentage of cell viability was calculated
very 2 days by dividing the total number of cells in the population
nfected by HIV-LAI (), HIV-BAL- (E) or HIV-YU-2- (X) infected cells by
he number of cells present in uninfected cultures (n), taken to be
00%. (B) Evolution of HIV DNA copies (HIV) 2 and 12 days after onset
f HIV addition. (C) RT-PCR analysis to detect the human glyceralde-
yde-3-phosphate dehydrogenase (G3PDH) transcripts, which serves
s a quantitative control in this experiment, the OAS transcripts (Vieil-
ard et al., 1994), and the HIV-gag (HIV) messengers, quantified 4 days
fter the onset of HIV infection.AI strain. Compared with untreated cells, we observedlow, temporary decrease in the cell viability (Fig. 3A),
orrelated with a number of HIV DNA copy per cell
10-fold lower than that observed in untreated cells, 2
ays after the onset of infection (Fig. 3B). All of these data
ndicated that a low production of IFN-b was sufficient to
nduce an antiviral state in TF-1 cells against the T
ell-tropic HIV-LAI strain.
Interestingly, at 4 days after HIV-LAI infection, in both
xperiments, we observed in the population containing
FN-b-transduced cells a ;2-fold increase of IFN-b pro-
uction (Table 1), correlated with an increase in the
verage number of HMB-KbHuIFNb integrations per cell
lose to 2 (Figs. 1B and 2), indicating a selective survival
f the IFN-b-transduced cells among HIV-LAI-surviving
ells.
IFN-b-transduction protects HIV-LAI-infected TF-1
ells from apoptosis. To further elucidate whether IFN-b
ransduction protects TF-1 cells against HIV-LAI strain in
he absence of a productive infection, we investigated
he presence and frequency of apoptotic cells. The ex-
osure of untransduced TF-1 cells to HIV-LAI resulted in
significant increase in the percentage of apoptotic
ells; 36% and 15% of apoptotic cells were detected, 7
nd 15 days, respectively, after the addition of HIV-LAI
ompared with ;5% of apoptotic cells detected in unin-
ected control cells (Table 2). On the contrary, in IFN-b-
ransduced cells exposed to HIV-LAI, the percentage of
poptotic cells remained at a steady level of 6% (Table 2),
ndicating that the low, constitutive expression of IFN-b
y TF-1 cells conferred protection against HIV-LAI-medi-
ted apoptosis. To determine the effect of IFN-b-trans-
uction on apoptosis, we used annexin V as a specific
arker for the early events of apoptosis (Koopman et al.,
994). As shown in Fig. 4 in neo-transduced control cells,
e observed a high level of apoptotic cells (22%) 1 day
fter the addition of heat-inactivated HIV-LAI particles,
uggesting that infection was not required for the induc-
ion of apoptosis. In contrast, in IFN-b-transduced cells,
he level of early apoptotic events remained as low as
hat in the control cells (8%) (Fig. 4), confirming the
TABLE 2
Percentages of Apoptotic Untransduced and
IFN-b-transduced TF-1 Cells after HIV-LAI Infection
Percent of FITC-positive
cellsa
Day 7 Day 15
UT UI 4 5
UT HIV 36 15
IF-UI 4 2
IF-T HIV 6 6
Note. UT, untransduced cells, IF-T, IFN-b-transduced cells; UI, unin-
ected cells; HIV, HIV-LAI-infected cells.a Days after HIV infection.
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244 CREMER, VIEILLARD, AND DE MAEYERrotective effect of IFN-b against HIV-mediated apopto-
is.
IFN-b induces high resistance against M cell-tropic
IV stains compared with IFN-a. We also investigated
he effect of exogenously added IFN-a2 or IFN-b on the
cell-tropic HIV strains. To this purpose, TF-1 cells were
ultivated in the presence of 100 U/ml IFN-a2b or IFN-b
nd infected with the HIV-BAL or HIV-YU-2. In both cases,
he treatment with IFN-a2b or IFN-b resulted in a similar
nduction of the (29-59-oligoadenylate synthetase (OAS)
xpression (Fig. 3C). In untreated cells, we observed a
ramatic decrease of the cell viability after infection with
IV-BAL or HIV-YU-2 (Fig. 3A). This decrease of cell
iability was correlated with an increase in HIV DNA
opy number per cell. Twelve days after the addition of
he virus, ;42% of the cells were infected by HIV-BAL or
IV-YU-2, as shown by PCR analysis (Fig. 3B). In addition,
high level of HIV-BAL- or HIV-YU-2-gag RNA transcripts
as detected 4 days after the onset of HIV infection (Fig.
C), and a p24 production of ;200 pg/105 cells (Fig. 5A)
as detected 6 days after the addition of the virus. This
igh HIV replication in TF-1 cells infected with M cell-
ropic HIV strain was correlated with the presence of a
arge proportion of HIV infectious particles (Fig. 5B). In
FN-a2b-treated cells infected by HIV-BAL or HIV-YU-2,
e observed a strong decrease in the cell viability (Fig.
A). In contrast, the cell viability remained at a steady
evel of ;80% in IFN-b-treated cells (Fig. 3A). Moreover,
n IFN-a2b-treated cells, we observed that ;14% or 6% of
he cells were HIV infected, 12 days after the addition of
FIG. 4. Flow cytometric analysis of early events of apoptosis in neo-
A and B) and IFN-b- (C and D) transduced cells 1 day after the addition
f heat-inactivated HIV-LAI particles (B and D). Cells were directly
tained with annexin-V-FITC and propidium iodide (PI). The percent-
ges of apoptotic cells corresponds to the total of the percentages of
he upper and lower right quadrants.IV-BAL or HIV-YU-2, respectively (Fig. 3B), and low lev- ols of HIV-gag transcripts were also detected in HIV-BAL-
nfected cells (Fig. 3C). In contrast, in IFN-b-treated cells,
he levels of HIV DNA copies and of HIV RNA transcripts
emained close to the background level (Figs. 3B and
C). Furthermore, after the addition of 100 U/ml of IFN-b,
he level of p24 release and the production of HIV infec-
ious particles were ;5-fold lower compared with IFN-
2b-treated cells (Figs. 5A and 5B). We also observed in
FN-b-transduced cells a strong resistance against M-
ropic HIV strains. As shown in Fig. 2, at 12 days after the
ddition of the virus, the level of HIV DNA copies re-
ained close to background values. In addition, the level
f p24 production remained inferior to 10 pg/105 cells
data not shown).
This demonstrated that the treatment of hematopoietic
rogenitor TF-1 cells with a low dose of IFN-b was more
fficient than a treatment with a comparable amount of
FN-a2b, specifically against M cell-tropic HIV strains
nd suggested that the block of HIV infection by IFN-b
ccurred at a stage of viral DNA integration or before it.
Down-regulation of the CCR-5 chemokine receptor ex-
ression by IFN-b. To determine whether IFN-b-medi-
ted resistance to M cell-tropic HIV strains resulted from
block that occurred at an early step of the HIV infec-
ious cycle, we analyzed by RT-PCR the expression of
wo b-chemokine receptors identified as cofactors for
he entry of HIV-1 into target cells. The CXCR-4 chemo-
ine receptor was shown to act as a coreceptor for T
ell-tropic strains and the CCR-5 as a coreceptor for M
FIG. 5. Inhibition of HIV replication in IFN-a2b- and IFN-b-treated
F-1 cells 6 days after the onset of HIV addition. (A) p24 production in
he culture medium of cells challenged with HIV-LAI (h), HIV-BAL (^),
r HIV-YU-2 (n) strains. (B) Titration of infectious HIV particles released
y untreated, IFN-a2b-treated, or IFN-b-treated cells at 6 days after the
nset of HIV-YU-2 infection, determined on P4.2 HeLa cells.
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245IFN-b-MEDIATED HIV RESISTANCE IN CD341 CELLSell-tropic viruses (Berger et al., 1998). Deichmann et al.,
1997) observed that CD341 hematopoietic progenitor
ells expressed both the CXCR-4 and the CCR-5 core-
eptors. As shown in Fig. 6A, TF-1 cells exhibited low
evels of CXCR-4 transcripts, ;6.8-fold lower compared
ith the level of expression obtained in the J. Jhan CD41
lymphocytic cell line. In addition, the level of CXCR-4
xpression was slightly modified after a treatment with
FN-a2b or IFN-b (Fig. 6A). On the contrary, the CCR-5
eceptor was highly expressed on TF-1 cells, and its
xpression was significantly decreased in IFN-b-treated
ells. We observed 7.1-fold less abundant transcripts in
FN-b-treated cells compared with untreated cells and
.7-fold lower compared with IFN-a2b-treated cells. In
FIG. 6. Detection of CXCR-4 and CCR-5 mRNA by RT-PCR analysis.
A) Untreated (UT), IFN-a2b-treated, and, IFN-b-treated TF-1 cells, 4
ays after the onset of HIV-YU-2 infection. For CXCR-4 mRNA, the T cell
ine J. Jhan served as positive control and water served as negative
ontrol. For CCR5 mRNA, the U937 promonocytic cell line served as
ositive control and water served as negative control. (B) neo-trans-
uced and IFN-b-transduced TF-1 cells 4 days after the onset of HIV
nfection.FN-b-transduced TF-1 cells, we also detected a 7.0-fold wecrease in the CCR-5 transcripts compared with neo-
ransduced TF-1 cells (Fig. 6B). As shown in Fig. 7, flow
ytometry then confirmed that compared with control
ells, in both IFN-b-transduced and IFN-b-treated cells,
here was a ;4-fold decrease in CCR-5 cell surface
xpression. Furthermore, the effect of IFN-a2b on CCR-5
xpression was 2-fold less pronounced than that of
FN-b.
These results demonstrate that IFN-b was more effi-
ient than IFN-a2b to inhibit the infection with M cell-
ropic HIV stains by the drastic decrease of the CCR-5
xpression.
DISCUSSION
The aim of the present study was to investigate the
ossibility of conferring an antiviral state to CD341 TF-1
ells, as a model of hematopoietic progenitor cells,
hrough a low constitutive expression of IFN-b and to
lucidate mechanisms by which type I IFNs confer HIV
esistance to these cells. We found that CD341 TF-1 cells
an be transduced by the HMB-KbHuIFNb retroviral vec-
or and that low constitutive expression of IFN-b offers
ignificant protection against HIV-LAI infection, as
hown by the survival of the CD41 fraction of TF-1 cells
nd the selective advantage of IFN-b-expressing cells
mong the IFN-b-transduced cell population. Moreover,
he engagement of the TF-1 cells in the myeloid pathway
ould explain that a productive HIV infection occurred
nly in cells infected with M cell-tropic HIV strains (Kita-
ura et al., 1989). Several studies suggest that the non-
-tropic strains can enter into macrophages, resulting
nto very low level virus replication (Schmidtmayerova et
l., 1992; Valentin et al., 1990). The mechanism of this
ery low level infection has been related to a block in
FIG. 7. Detection of CCR-5 expression by flow cytometry in untreated
UT), IFN-a2b-treated, and IFN-b-treated TF-1 cells 2 days after the
ddition of 100 U/ml recombinant IFN, as well as in neo- and IFN-b-
ransduced TF-1 cells, 2 days after transduction. The percentage of
CR-5 positive cells was determined by single color analysis. Cells
ere stained with anti-CCR-5-FITC monoclonal antibody; 10,000 events
ere acquired. White histograms show the isotype-matched controls.
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246 CREMER, VIEILLARD, AND DE MAEYEReverse transcription. The reason for this observation is
ot known but could involve intracellular events influ-
nced by the viral envelope and cytokine production
Schrier et al., 1990).
In untransduced cells infected with the T cell-tropic
IV-LAI strain, we observed only a transitory infection, as
hown by the presence of HIV DNA copies in cells,
etectable during ;4 days after the addition of the virus,
nd the decrease in the percentage of the CD41 cells in
he culture. Several studies have reported that indirect
echanisms acting on CD341 cells may be responsible
or the AIDS-associated hematopoietic suppression
Donahue et al., 1987; Molina et al., 1990; Scadden et al.,
989). This hypothesis is reinforced by analysis of the
poptosis induced by HIV. In untreated cells challenged
ith HIV-LAI, we observed a strong induction of apopto-
is, as previously described by Zauli et al. (1994). In
FN-b-transduced cells, a similar level of apoptosis was
etected in uninfected and HIV-LAI-infected cells. This
revention of apoptosis in IFN-b-transduced TF-1 cells
ould contribute to their high resistance to HIV-1 infec-
ion.
Additional experiments were performed to compare
he effects of IFN-a2b and IFN-b on HIV resistance
gainst M cell-tropic HIV strains. In cells infected by M
ell-tropic HIV strains, we observed a higher HIV resis-
ance conferred by IFN-b compared with IFN-a2b. After
n IFN-a2b treatment, the number of HIV DNA copies
nd the production of HIV particles were not significantly
ifferent from untreated cells, but the infectivity of HIV-
U-2 particles was less pronounced. In cells treated with
FN-b, the virus production remained at a very low level.
he inhibitory effect of type I IFNs on HIV replication has
een shown to affect both early and late steps of the
irus life cycle. Many studies have shown that in T cells
nd in monocytes, antiviral effects of IFN-a and -b take
lace at early steps of the HIV life cycle, resulting in a
educed viral DNA, RNA, and protein synthesis (Baca-
egen et al., 1994; Meylan et al., 1993). Shirazi et al.
1993) demonstrated that the inhibition of HIV replication
as detected only when T cells were treated with IFN-
2b before HIV infection, indicating that IFN-a interferes
ith an early step of the HIV infectious cycle that occurs
efore the integration of the proviral DNA. In a previous
eport, we demonstrated that the inhibition of HIV repli-
ation in lymphocytes by IFN-b transduction occurred at
stage before reverse transcription (Vieillard et al.,1994).
or numerous viruses, including HIV, attachment to the
eceptor is followed by a redistribution or capping of the
irus particles on the cell surface. IFN-b treatment in-
uces an inhibition of the lateral mobility of the cell
urface receptors for the lectin concanavalin A, resulting
n a significant reduction in capping (Pfeffer et al., 1980).
n addition, some results suggest an important relation-
hip between the lipid composition of the cell membrane
nd infection with some viruses. In this respect, it may be selevant that IFNs can block fusion of the HIV envelope
rotein and the cellular membrane (Aloia et al., 1993). In
ddition, IFN-a2 exerts an effect on the terminal stage of
he HIV life cycle. In IFN-a2-treated cells, the released
IV particles were 100- to 1000-fold less infectious com-
ared with particles released from untreated cells be-
ause of a defect in gp120 assembly into the mature viral
article (Hansen et al., 1992).
Our study provides evidence that the protection of TF-1
y IFN-b against M cell-tropic strains is partially medi-
ted by down-regulation of the CCR-5 expression. The
egulation of chemokine receptor expression by cyto-
ines may be important for the regulation of chemokine
ction. Interleukin-2 has been reported to induce both
CR-1 and CCR-2 expression in T and NK cells
Loetscher et al., 1996; Polentarutti et al., 1997), and
ranulocyte colony-stimulating factor have been shown
o up-regulate CXR-1 and CXR-2 expression in polymor-
honuclear leukocytes (Lloyd et al., 1995). In contrast,
FN-g and tumor necrosis factor-a down-regulated
CR-2 and CXCR-2 expression, respectively (Asagoe et
l., 1998; Penton-rol et al., 1998), and IFN-a down-regu-
ated CXCR-4 expression on peripheral blood mononu-
lear cells (PBMCs) (Shirazi et al., 1998). Of the chemo-
ine receptors, CCR-5 is the most important for viral
nfection because it is the principal receptor for primary
acrophage-tropic viruses, and individuals homozygous
or a defective CCR-5 allele (delta32/delta32) are highly
esistant to infection with HIV-1 (Dean et al., 1996; Liu et
l., 1996; Samson et al., 1996). In addition, anti-CCR-5
ntibodies inhibit the infection of PBMCs by M cell-tropic
IV-1 strains (Wu et al., 1997). Novel strategies are being
mplemented to examine mechanisms to sequester or
revent the expression of chemokine receptors to make
ells resistant to infection with HIV (Cairns and D’Souza,
998; Moore, 1997).
Gene therapy is based on the premise that insertion of
nti-HIV genes into target cells will render them resistant
o HIV infection and/or replication (Bridges and Sarver,
995; Yu et al., 1994). Many technological difficulties exist
n adapting this strategy to large-scale clinical testing,
ncluding inefficient ability to target viral reservoirs, ex-
ensive, and labor-intensive ex vivo manipulations of
arget cells. Some of these obstacles may be resolved
ith the use of pluripotent stem cells with self-renewal
apacity, which will permit the entry of gene therapy into
he mainstream of therapeutic options available for in-
ected individuals (Bahner et al., 1996). Autologous or
llogeneic transplantation with IFN-b-transduced pro-
enitor cells thus might allow the permanent repopula-
ion of all hematopoietic lineages of the immune system
ith intracellularly immunized cells. However, we ob-
erved that the HIV protection against M cell-tropic
trains was ^10-fold less pronounced when HIV infec-
ion took place before IFN-b transduction (data not
hown), suggesting that the antiviral effect of IFN-b is
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247IFN-b-MEDIATED HIV RESISTANCE IN CD341 CELLSore efficient in uninfected cells. This is in line with our
revious results that demonstrated that efficient HIV re-
istance was obtained only in PBLs derived from HIV-
nfected donors with ^200 CD41 T cells/mm3 of periph-
ral blood (Vieillard et al., 1997).
The present results, together with those previously
eported, are encouraging for the further exploration of a
ene transfer program using the IFN-b transduction of
ematopoietic CD341 progenitor cells.
MATERIALS AND METHODS
Cell lines and IFNs. Human CD341 TF-1 cells (Kita-
ura et al., 1989) were cultured at a density of 105
ells/ml in RPMI-1640 medium (Gibco Life Technologies,
ergy-Pontoise, France) supplemented with 10% fetal
alf serum (FCS; ATGC Biotechnologie, Noisy le Grand,
rance) and 3 mg/ml human recombinant interleukin-3
IL-3; R&D Systems, Abingdon, UK). Human P4-2 HeLa
ells (Charneau et al., 1994) were cultured in DMEM
Gibco) supplemented with 10% FCS. Recombinant hu-
an IFN-a2b (Introna, Schering Plough) and Escherichia
oli-derived recombinant IFN-b were used at 100 U/ml.
HIV strains. HIV-LAI stock was prepared as described
reviously (Vieillard et al., 1995) and corresponded to a
everse transcriptase activity of 2 3 106 cpm/ml with an
nfectivity of 3 3 106 TCID50. HIV-YU-2 and HIV-BAL
tocks were prepared by passage of the virus in human
BL cultures. At days 10–15 after infection, supernatant
rom the HIV-infected cultures were clarified by centrifu-
ation, aliquoted, and stored at 280°C. Virus stocks
ere titered by triplicate end point dilution in PBMC
ultures, using p24 antigen production. HIV-YU-2 stock
ontained 40 ng/ml p24 with an infectivity of 2.5 3 105
CID50. HIV-BAL stock contained 100 ng/ml p24. Inacti-
ated HIV-LAI particles were obtained by heating at 59°C
or 45 min as described previously (Zauli et al., 1996).
IFN-b transduction of TF-1 cells. One million TF-1 cells
ere transduced with the HMB-KbHuIFNb retroviral vec-
or by coculturing the cells for 3 days on C-CRIP-HMB-
bHuIFNb packaging cells (Vieillard et al., 1994; 1997) in
MDM medium (Gibco) supplemented with 10% FCS, 3
g/ml IL-3, and 10 mg/ml protamine sulfate (Sigma-Al-
rich, Saint Quentin Fallavier, France). The neo-trans-
uced control cells consisted of TF-1 cells cocultured for
days on C-CRIP-HMB-Neo packaging cells (Hawley et
l., 1989). The transduction efficacy was estimated by
CR amplification, and the absence of murine packaging
ells was verified by PCR analysis with a murine a-globin
et primer, as described previously (Vieillard et al., 1997).
IFN titrations. IFN titrations were carried out on human
ISH cells in microtiter plates (40,000 cells/well), using
SV as the challenge virus. Cells were incubated over-
ight in 0.15 ml with 2-fold IFN dilutions and then infected
ith vesicular stomatitis virus at 1022 PFU/cell. One IFN onit corresponds to the reciprocal of the dilution protect-
ng 50% of the cells.
Fluorescence-activated cell sorter analysis. TF-1 cells
ere incubated with fluorescein-isothiocyanate-conju-
ated anti-CD4 (Becton Dickinson, Le Pont de Claix,
rance), anti-CD34 (Becton Dickinson), or anti-CCR-5
R&D Systems) monoclonal antibodies for 30 min. The
ells were then washed three times with PBS/1% BSA,
esuspended in PBS, and analyzed by flow cytometry on
FACScan (Becton Dickinson). Isotype-matched Ig
erved as negative controls (Becton Dickinson).
Quantification of HIV replication. Two million of un-
ransduced, IFN-b-transduced, or IFN-treated TF-1 cells
ere infected at an m.o.i. of 0.01, with the T cell-tropic
IV-LAI strain or with the M cell-tropic HIV-BAL or HIV-
U-2 strains, during 2 h in the presence of 10 mg/ml
rotamine sulfate. After washing in PBS, the cells were
esuspended in culture medium. Uninfected cell popula-
ions were run in parallel. Every 2 days, culture super-
atants were collected and frozen at 280°C for subse-
uent assays, and the cells were resuspended in fresh
ulture medium. We determined the cell viability, the
umber of HIV DNA copies by PCR amplification, the
resence of HIV RNA transcripts by RT-PCR, and virus
eleased in the culture supernatants by an enzyme-
inked immunosorbent assay for HIV p24 antigen (Du-
ont de Nemours, Les Ulis, France). The production of
nfectious HIV particles was determined on P4.2 HeLa
ells, as described previously (Charneau et al., 1994).
PCR analysis of HIV infection and of transduction effi-
acy. DNA extracts were prepared as described previ-
usly (Seif et al., 1991). One hundred nanograms of DNA
ere amplified by PCR for 30 cycles in the presence of 1
M [a-33P]dCTP (10 mCi/mM; NEN Life Science Prod-
cts, Le Blanc Mesnils, France). The following primers
ere used: a HIV gag primer set, 59-ATCAAGCAGCCAT-
CAAAT-39 and 59-CTTTTGGTCCTTGTCTTATGTC-39; a
MB-KbHuIFNb transgene primer set, 59-GTTCAG-
CAAAGTCTTAGTC-39 and 59-GATGATAGACATTAGC-
AGG-39; HMB-neo sequences, 59-ATGGATTGCACG-
AGGTTCT-39 and 59-CTCGCTCGATGCGATGTTTC-39;
nd a a1-globin primer set, 59-ACCATGGTGCTGTCTC-
TGC-39 and 59-GCATGGCCACGAGGCTCCA-39. The
CR products were detected by autoradiography after
lectrophoresis on 4% nondenaturing polyacrylamide
els. DNA of each band was quantified using a Phos-
horImager (Molecular Dynamics, Sevenoaks, UK). Se-
ial 10-fold dilution of DNA preparations from HIV-LAI-
nfected J. Jhan cells and from plasmid-transfected U937
ells containing one copy of HIV or one copy of IFN-b-
ransgene per cell, respectively (Mace´ et al., 1991; Vieil-
ard et al., 1995) were used as standards and amplified in
ach reaction to determine interassay variability and
ensitivity.
Flow cytometric analysis of apoptotic cells. Detection
f apoptotic cell death was realized using the terminal
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248 CREMER, VIEILLARD, AND DE MAEYEReoxynucleotidyl transferase (TdT)-mediated dUTP nick
nd-labeling (TUNEL) methodology (Piqueras et al.,
996). TF-1 cells were fixed in a PBS solution containing
% paraformaldehyde (PFA) for 1 h at 4°C washed three
imes in PBS/1% BSA and resuspended during 1 h at
20°C in 70% ethanol. The cells were incubated in
uffer reaction containing dUTP fluorescein-conjugated
Promega, Charbonnie`res, France) for 30 min at 4°C. Ten
nits of TdT (Promega) were added for 1 h at 37°C, and
.5 M EDTA was added to stop the reaction. The cells
ere washed three times in PBS/1% BSA, fixed 10 min in
PBS/1% PFA solution at 4°C, resuspended in PBS, and
nalyzed with the FACScan. Analysis of early events of
poptosis was realized with the Annexin-V apoptosis
etection kit (R&D Systems) at day 1 after the addition of
eat-inactivated HIV-BRU particles as described previ-
usly (Koopman et al., 1994).
Chemokine receptor expression. Total RNAs were iso-
ated using the RNA isolation kit (Stratagene, Montig-
y-le-Bretonneux, France). cDNA products were ob-
ained from 1 mg of total RNA treated with DNase I
Promega) using the First Strand Synthesis kit (Pharma-
ia Biotech, Orsay, France). One-sixteenth of the cDNA
roducts was amplified by PCR for 30 cycles in the
resence of 1 mM [a-33P]dCTP (10 mCi/mM; NEN Life
cience Products) to detect the human glyceraldehyde-
-phosphate dehydrogenase (G3PDH) transcripts as a
uantitative control. To estimate chemokine receptor ex-
ression, cDNA products were amplified by PCR for 35
ycles, using a CXCR-4 primer set 59-ACGTCAGTGAG-
CAGATG-39 and 59-GATGACTGTGGTCTTGAG-39 and a
CR-5 primer set 59-GTCCAATCTATGACATCA-39 and 59-
GTGTAATGAAGACCTTC-39. The reaction products
ere detected by autoradiography after electrophoresis
n 4% nondenaturing polyacrylamide gels and were
uantified using the PhosphorImager.
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